Biomarkers | Patients with adverse outcomes (n = 18) | Patients with favorable outcomes (n = 13) |
---|---|---|
IL-6 (pg mL−1) | 121.1 (31.4–334.3)* | 33.2 (13.0–61.7) |
IL-1β (pg mL−1) | 2.3 (2.1–2.5) | 2.3 (2.0–2.5) |
TNF-α (pg mL−1) | 16.6 (10.8–32.7) | 16.5 (13.3–21.0) |
NSE (μg L−1) | 0.55 (0.44–1.10) | 1.31 (0.46–2.15) |
S100B (ng mL−1) | 0.08 (0.06–0.13) | 0.08 (0.07–0.15) |
S100 (ng L−1) | 13.5 (5.8–31.0) | 22.4 (1.3–136.4) |
CKBB (ng mL−1) | 2.1 (1.5–3.5) | 1.9 (1.4–2.4) |
L/C ratio | 19.0 (2.64–47.89)* | 0.12 (0.04–0.36) |